
Never has a pharma or biotech’s use of capital been under more scrutiny. Consequently, regar...
Never has a pharma or biotech’s use of capital been under more scrutiny. Consequently, regar...
Antibody-drug conjugates have arisen as a groundbreaking class of targeted cancer therapies,...
The UK’s record £86 billion R&D pledge (worth £22.5 billion a year by FY 2029/30) will f...
As APAC Managing Partner at Board & Executive Partners (a Barrington James com...
Singapore's strategic position at the heart of Asia-Pacific and it's deep pool of scientific...
Regeneron Pharmaceuticals has agreed to acquire almost all of 23andMe’s business lines, whic...
Six-Year Specialist in Regulatory Affairs & Quality Talent For six years, WanYun Ni...
Since Donald Trump has started his second term in office, it has been a turbulent 100+ days....